News
Public · Published
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported third quarter 2026 financial results and said it had $431.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, plus an expected $12 million GSK milestone in the fourth quarter of 2026.
Published:
Updated:
What happened
Wave Life Sciences reported third quarter 2026 financial results and said it had $431.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, plus an expected $12 million GSK milestone in the fourth quarter of 2026.
Confirmed
Global impact / market context
The $431.0 million cash balance and expected $12 million payment support a runway into the third quarter of 2028, which means the company may fund its registrational trial planning and multiple Phase 2a programs without needing to raise new money soon.
Analyst inference
Wave is a clinical-stage RNA medicines company with several trials and regulatory submissions planned. Its spending on registrational trial preparation and Phase 2a dosing affects cash use, and the GSK collaboration candidate selection adds a potential milestone source of revenue.
Analyst inference
What to watch
- Wave expects to receive a $12 million milestone from GSK in the fourth quarter of 2026, which would add to its reported cash balance. Confirmed
- The company plans a registrational trial for WVE-006 in AATD with an interim analysis for potential accelerated approval based on AATD biomarkers. Proposed
- Investors may watch whether Wave's cash runway into 3Q 2028 holds as trial costs rise, since new borrowing or share sales could change its financial position. Analyst inference